An investor in NYSE:NVO shares filed a lawsuit over alleged Securities Laws violations by Novo Nordisk A/S.
Investors who purchased shares of Novo Nordisk A/S (ADR) (NYSE:NVO) have certain options and for certain investors are short and strict deadlines running. Deadline: March 13, 2017. NYSE:NVO investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The plaintiff claims that between April 30, 2015 to October 27, 2016 Novo Nordisk A/S reported allegedly materially false and misleading earnings and forecasts in that they were inflated through the collusive price fixing of the Company’s insulin drugs.
The Complaint also alleges that Novo Nordisk A/S misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.
Novo Nordisk A/S reported that its annual Total Revenue rose from $12.71 million in 2014 to $15.45 million in 2015 and that its Net Income increased from over $3.84 million in 2014 to $4.99 million in 2015
Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) rose to as high as $57.44 per share in June 2016. On November 23, 2017 shares of Novo Nordisk A/S (ADR) (NYSE:NVO) declined to as low as $30.89 per share.
On January 24, 2017, NYSE:NVO shares closed at $34.79 per share.
Those who purchased NYSE:NVO shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego